Axsome Therapeutics, Inc. (AXSM)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Axsome Therapeutics, Inc. (AXSM)
Go deeper and ask any question about AXSM
Company Performance
Current Price
as of Sep 13, 2024$93.67
P/E Ratio
N/A
Market Cap
$4.5B
Description
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Metrics
Overview
- HQNew York, NY
- SectorHealth Technology
- IndustryBiotechnology
- TickerAXSM
- Price$93.67+2.09%
Trading Information
- Market Cap$4.50B
- Float81.59%
- Average Daily Volume (1m)438,505
- Average Daily Volume (3m)576,555
- EPS-$6.51
Company
- Revenue$291.49M
- Rev Growth (1yr)86.65%
- Net Income-$79.35M
- Gross Margin88.63%
- EBITDA Margin-84.93%
- EBITDA-$74.03M
- EV$3.71B
- EV/Revenue12.71
- P/EN/A
- P/S15.29
Documents
SEC Filings
Factset Street Account